Primary Sclerosing Cholangitis Market Outlook Highlights Rising Demand and Expanding Treatment Landscape Throughout the Forecast Period (2025-2034) | DelveInsight
PR Newswire —
According to DelveInsight's analysis, the primary sclerosing cholangitis market is anticipated to grow during the forecast period (2025–2034), driven by the launch of emerging therapies such as LB-P8 (LISCure Biosciences), Volixibat (Mirum Pharmaceuticals), IQIRVO (Elafibranor) (Ipsen),...